Gregory R. Ott

1.4k total citations
34 papers, 948 citations indexed

About

Gregory R. Ott is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gregory R. Ott has authored 34 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Organic Chemistry and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gregory R. Ott's work include Cancer therapeutics and mechanisms (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Neuroblastoma Research and Treatments (8 papers). Gregory R. Ott is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Neuroblastoma Research and Treatments (8 papers). Gregory R. Ott collaborates with scholars based in United States, United Kingdom and Italy. Gregory R. Ott's co-authors include Amos B. Smith, Mangeng Cheng, Bruce D. Dorsey, Thelma S. Angeles, Mark S. Albom, Arup K. Ghose, Weihua Wan, Lisa D. Aimone, Bruce Ruggeri and Clayton H. Heathcock and has published in prestigious journals such as Journal of the American Chemical Society, Gastroenterology and Cancer Research.

In The Last Decade

Gregory R. Ott

34 papers receiving 892 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory R. Ott United States	20	492	462	172	163	95	34	948
Ted L. Underiner United States	18	331 0.7×	388 0.8×	154 0.9×	96 0.6×	30 0.3×	31	763
Xin‐Jie Chu United States	13	382 0.8×	580 1.3×	425 2.5×	78 0.5×	77 0.8×	25	1.1k
Timothy P. Heffron United States	14	297 0.6×	322 0.7×	200 1.2×	167 1.0×	34 0.4×	21	808
Butrus Atrash United Kingdom	18	260 0.5×	767 1.7×	323 1.9×	58 0.4×	41 0.4×	39	1.2k
Peter G. Goekjian France	24	1.0k 2.1×	907 2.0×	126 0.7×	38 0.2×	118 1.2×	65	1.7k
Kiyohiro Nishikawa Japan	21	348 0.7×	767 1.7×	397 2.3×	53 0.3×	210 2.2×	56	1.4k
William D. Shrader United States	18	245 0.5×	735 1.6×	75 0.4×	114 0.7×	22 0.2×	30	1.2k
Takaaki A. Fukami Japan	12	223 0.5×	564 1.2×	366 2.1×	379 2.3×	43 0.5×	21	956
Robert A. Galemmo United States	19	262 0.5×	494 1.1×	158 0.9×	33 0.2×	50 0.5×	46	1.0k
Melvin J. Yu United States	17	326 0.7×	402 0.9×	422 2.5×	103 0.6×	205 2.2×	30	1.1k

Countries citing papers authored by Gregory R. Ott

Since Specialization

Citations

This map shows the geographic impact of Gregory R. Ott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory R. Ott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory R. Ott more than expected).

Fields of papers citing papers by Gregory R. Ott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory R. Ott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory R. Ott. The network helps show where Gregory R. Ott may publish in the future.

Co-authorship network of co-authors of Gregory R. Ott

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory R. Ott. A scholar is included among the top collaborators of Gregory R. Ott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory R. Ott. Gregory R. Ott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roper, Jason M., George E. Johnson, Jakub Kostal, et al.. (2025). Using N‐Nitrosodiethanolamine (NDELA) and N‐Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency‐Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data. Environmental and Molecular Mutagenesis. 66(4). 155–171. 1 indexed citations

Ator, Mark A., Alastair Brown, Jason Brown, et al.. (2020). Structure-Based Drug Discovery of N -(( R )-3-(7-Methyl-1 H -indazol-5-yl)-1-oxo-1-((( S )-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3- d ][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine. Journal of Medicinal Chemistry. 63(14). 7906–7920. 13 indexed citations

Ott, Gregory R. & David A. Favor. (2017). Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle. Bioorganic & Medicinal Chemistry Letters. 27(18). 4238–4246. 13 indexed citations

Chervoneva, Inna, Sankar Addya, Gregory R. Ott, et al.. (2016). The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. Breast Cancer Research. 18(1). 37–37. 24 indexed citations

Ghose, Arup K., Gregory R. Ott, & Robert L. Hudkins. (2016). Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization. ACS Chemical Neuroscience. 8(1). 147–154. 26 indexed citations

Mesaros, Eugen F., Thelma S. Angeles, Mark S. Albom, et al.. (2015). Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase. Bioorganic & Medicinal Chemistry Letters. 25(5). 1047–1052. 14 indexed citations

Mesaros, Eugen F., Gregory R. Ott, & Bruce D. Dorsey. (2014). Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opinion on Therapeutic Patents. 24(4). 417–442. 20 indexed citations

Gingrich, Diane E., Joseph G. Lisko, Mangeng Cheng, et al.. (2012). Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry. 55(10). 4580–4593. 31 indexed citations

Cheng, Mangeng, Matthew R. Quail, Diane E. Gingrich, et al.. (2011). CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics. 11(3). 670–679. 59 indexed citations

10.

Zificsak, Craig A., Jay Theroff, Lisa D. Aimone, et al.. (2011). Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(13). 3877–3880. 18 indexed citations

11.

Tripathy, Rabindranath, Robert J. McHugh, Arup K. Ghose, et al.. (2011). Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of selectivity by a benzyloxy group. Bioorganic & Medicinal Chemistry Letters. 21(24). 7261–7264. 27 indexed citations

12.

Wells‐Knecht, Kevin J., Gregory R. Ott, Mangeng Cheng, et al.. (2011). 2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation. Chemical Research in Toxicology. 24(11). 1994–2003. 8 indexed citations

13.

Milkiewicz, Karen L. & Gregory R. Ott. (2010). Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opinion on Therapeutic Patents. 20(12). 1653–1681. 16 indexed citations

14.

Albom, Mark S., Thelma S. Angeles, Jean Husten, et al.. (2010). Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(1). 164–167. 22 indexed citations

15.

Mesaros, Eugen F., Jason P. Burke, Jonathan D. Parrish, et al.. (2010). Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorganic & Medicinal Chemistry Letters. 21(1). 463–466. 27 indexed citations

16.

Cheng, Mangeng & Gregory R. Ott. (2010). Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma. Anti-Cancer Agents in Medicinal Chemistry. 10(3). 236–249. 30 indexed citations

17.

Lu, Zhonghui, Gregory R. Ott, Rajan Anand, et al.. (2008). Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE): Discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1′ substituents. Bioorganic & Medicinal Chemistry Letters. 18(6). 1958–1962. 53 indexed citations

18.

Ott, Gregory R., Naoyuki Asakawa, Rui‐Qin Liu, et al.. (2008). α,β-Cyclic-β-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorganic & Medicinal Chemistry Letters. 18(4). 1288–1292. 13 indexed citations

19.

Ott, Gregory R., Naoyuki Asakawa, Zhonghui Lu, et al.. (2008). Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents. Bioorganic & Medicinal Chemistry Letters. 18(5). 1577–1582. 41 indexed citations

20.

Schoeniger, Luke O., Kenneth A. Andreoni, Gregory R. Ott, et al.. (1994). Induction of heat-shock gene expression in postischemic pig liver depends on superoxide generation. Gastroenterology. 106(1). 177–184. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact